Diabetes Clinical Trials in Dallas

Showing 401-420 of 593 trials

Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus

NCT00722917

The purpose of this study is to evaluate the safety and effectiveness of multiple doses of TAK-379, once daily (QD), in subjects with type 2 diabetes mellitus.

Diabetes Mellitus

Takeda323 participantsStarted Jul 2008

Artesia, California, United States • Norwalk, California, United States • Santa Ana, California, United States +5 more locations

COMPLETEDNA< 1 mile

Pet Ownership and Glucose Control in Type 1 Diabetes

NCT01733524

The investigators' long-term goal is to discover novel, inexpensive and feasible strategies to improve the management and well-being of youth with T1DM. The specific objective of this proposal is to quantify the impact of responsible pet ownership on the glycemic control and health related quality of life in youth with T1DM.

Type 1 Diabetes Mellitus

University of Texas Southwestern Medical Center29 participantsStarted Oct 2012

Dallas, Texas, United States

COMPLETEDPhase 3< 1 mile

A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

NCT01455870

Phase 3 study to compare treatment with ITCA 650 to sitagliptin when added to metformin monotherapy in patients with type 2 diabetes.

Type 2 Diabetes

Intarcia Therapeutics535 participantsStarted May 2013

Birmingham, Alabama, United States • Chandler, Arizona, United States • Long Beach, California, United States +51 more locations

Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus

Pet Ownership and Glucose Control in Type 1 Diabetes

A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

Diabetes Trials in Other Cities

TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes

Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus

Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

Diabetes Technology Study of Real-Time Glucose Alerts in the Team Management of Diabetes

Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

OMT of Somatic Dysfunction and Chronic Low Back Pain in Patients With Type 2 Diabetes Mellitus

Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes

G5® Mobile Continuous Glucose Monitoring System Automated vs. Manual Sensor Applicator

Multiple Ascending Dose Study in Subjects With Type 2 Diabetes

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes

Safety Study of BMS-770767 in Subjects With Type 2 Diabetes

Other Conditions in Dallas